Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition ...
BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 (ots/PRNewswire) -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than ...
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA). Agendia received FDA 510(k) clearance for its MammaPrint(R) breast cancer recurrence test in early 2007. It remains the first and only ...
Irvine, California and Amsterdam (ots/PRNewswire) - - Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online ...
Irvine, California and Amsterdam (ots/PRNewswire) - Panel's Recommendations Reinforce Clinical Value of Tests Such as BluePrint(R) Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen International Breast Cancer Conference (2011) Expert Panel's recommendations ...
Irvine, California and Amsterdam (ots/PRNewswire) - - Company Will Develop Companion Diagnostics With Consortiums of Leading European Cancer Centers and Translational Research Groups Agendia, a global innovator in molecular cancer diagnostics, announced today that, together with thought-leading collaborators in clinical centers and translational research groups, it has ...
Amsterdam (ots/PRNewswire) - Agendia (the "Company"), a commercial-stage molecular diagnostic company with operations in the Netherlands and the United States, announces today its intention to raise new funds through an initial public offering ("IPO") on NYSE Euronext in Amsterdam. Agendia is focused on the discovery, development and commercialisation of molecular diagnostic products that help physicians to make ...
Amsterdam and Irvine, California (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that it has partnered with AstraZeneca and The Netherlands Cancer Institute (NKI) to accelerate the development of targeted therapies for colorectal cancer patients. The announcement marks ...
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced the hiring of David Macdonald as the company's Chief Operating Officer, Mark Willig as Executive Vice President of North American Sales, and Doug Bradley as Vice President of Global Marketing. ...
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration (FDA) clearance for MammaPrint(R), its widely used breast cancer recurrence assay. The new clearance is comprised of two additional Agilent Microarray scanners and two ...
Irvine, California, and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that together with several groups of scientific collaborators it has identified a major role for TSPYL5, one of its MammaPrint breast cancer prognosis genes, in the genesis of breast cancer. The study entitled: "TSPYL5 suppresses p53 levels ...
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the Netherlands, it has published the first independent validation study of its colon cancer recurrence test "ColoPrint" ...
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company's MammaPrint test. Agendia's contract with Humana expands the coverage for MammaPrint by more than 17 million lives. In November 2009, Palmetto GBA, California's Part B Medicare administrator, ...
Irvine, California, and Amsterdam, August 5, 2010 (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to ...
Irvine, California, and Amsterdam, July 15, 2010 (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. on the federal regulation of laboratory developed tests (LDTs). Jointly organized by the Food and Drug Administration ...
Huntington Beach, California and Amsterdam, June 4, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), ...
HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 (ots/PRNewswire) -- Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with ...
HUNTINGTON BEACH, California and AMSTERDAM, April 20, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today it has closed an agreement with Ferrer inCode for the commercialization of Agendia's FDA-cleared breast cancer recurrence test MammaPrint in Latin America. For the successful commercialization of MammaPrint, ...
HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor ...
HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites. I-SPY 2 is an exciting and groundbreaking new clinical trial model that will help scientists quickly and efficiently test the most ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receive commercial samples of ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians. Over the past three years, the FDA has issued four clearances for ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that it will be presenting six studies focusing on MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium (SABCS), one of the premiere conferences in breast cancer research worldwide. The SABCS will take place December ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test. MammaPrint is Agendia's FDA-cleared breast ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) - - International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence ...
Huntington Beach, California, and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced its strong support of Genentech's Citizen's Petition. Filed on December 5, 2008, Docket No. FDA-2008-P-0638-0001/CP petitions that all in vitro diagnostic tests be held to one ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) - - Agendia Increases U.S. Footprint with Domestic Executive Team and Operations Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The laboratory is fully-licensed and compliant with the Clinical Laboratory Improvements Amendments (CLIA) as administered ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American ...
Huntington Beach, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced that the Company is scheduled to present at the 16th Anniversary "Future Leaders in the Biotech Industry" Conference on Thursday, April 2, 2009. Presented by BioCentury and Thomson Reuters, the Future Leaders conference has built a ...
HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gallen Breast ...